ED50 of propofol combined with nalbuphine in painless gastroscopy

ED50 and ED95 of propofol combined with low-dose nalbuphine in painless gastroscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053204

Enrollment

Unknown

Registered

2021-11-14

Start date

2021-11-15

Completion date

Unknown

Last updated

2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group 1:Nalbuphine 0.1mg/kg

Group 2:Nalbuphine 0.15mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients with elective gastroscopic surgery, ASAI-II grade; 2. Aged 18-60 years; 3. BMI 18-25 kg/m^2; 4. Communication is normal; 5. Voluntarily test and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe respiratory and circulatory system diseases: such as severe coronary heart disease, chronic obstructive pulmonary disease, etc.; 2. Endocrine system diseases: such as pituitary tumor, severe diabetes, hypercortisol syndrome, pheochromocytoma, etc.; 3. Mental and psychological diseases: such as schizophrenia, depression, history of chronic analgesic drug use, history of alcoholism, opioid dependence; 4. History of allergy to anesthetics.

Design outcomes

Primary

Measure	Time frame
Median effective dose;Dosage of Propofol;Dosage of Nalbuphine;	—

Secondary

Measure	Time frame
Recovery time;Duration time given initial dose of Propofol;Respiratory depression;Duration of procedure;Adverse reactions;	—

Countries

China

Contacts

Public ContactTang Lili

The First Affiliated Hospital of Anhui Medical University

tanglilys@163.com+86 18654110160

Outcome results